(Total Views: 667)
Posted On: 08/15/2020 1:49:18 PM
Post# of 154067
blafarm,
One question I had regarding the numbers is why the DSMB looked at 149 patients.
Up to this analysis even Nader implied that the patients had to have gone through 28 days of treatment. However if you subtract 28 days from Aug 3 you are back at 7/6. There is no way we had 149 patients with 28 days in on 7/6 given all the s/c updates in between.
NP himself said ~100 patients would be looked at by the DSMB just the week before the PR.
It may be that the DSMB looked at 14 day and 28 day patients??
Would be nice to have a clear understanding of how this will play out.
One question I had regarding the numbers is why the DSMB looked at 149 patients.
Quote:
VANCOUVER, Washington, Aug. 04, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company", a late-stage biotechnology company, announced today an independent Data Safety Monitoring Committee (“DSMC”) completed its first safety review of the ongoing Phase 3 clinical trial (CD12) in patients with severe and critical COVID-19 and reported it saw no cause to modify the study. The DSMC reviewed compiled safety data from 149 subjects enrolled in the CD12 trial. The DSMC did not raise any concerns regarding safety and recommended that the trial continue.
Up to this analysis even Nader implied that the patients had to have gone through 28 days of treatment. However if you subtract 28 days from Aug 3 you are back at 7/6. There is no way we had 149 patients with 28 days in on 7/6 given all the s/c updates in between.
NP himself said ~100 patients would be looked at by the DSMB just the week before the PR.
It may be that the DSMB looked at 14 day and 28 day patients??
Would be nice to have a clear understanding of how this will play out.
(0)
(0)
